Lausanne: Several simple and 
inexpensive techniques make it possible to store antiviral-vaccines at 
room temperature for several months. This discovery by EPFL researchers 
and partners could make a difference in inaccessible areas and 
developing countries where maintaining cold-chain transportation of 
vaccines is complicated and expensive. Shipping vaccines in an
 unbroken temperature-controlled supply chain (a “cold chain”) all the 
way to recipients is a major logistical and financial challenge in 
remote areas and developing countries. According to Doctors Without 
Borders, the need to keep vaccines within a temperature range of 2-8°C 
is one of the main factors behind low immunization-coverage rates.
Researchers
 at EPFL’s Supramolecular Nanomaterials and Interfaces Laboratory 
(SUNMIL), in collaboration with scientists in Milan, Turin, Leiden, and 
Oregon, have come up with three simple and inexpensive vaccine additives
 to get around this obstacle. Using minute quantities of nanoparticles, 
or FDA-approved polymer (polyethylene glycol), or higher amounts of 
sucrose, they were able to stabilize vaccines at room temperature for 
several weeks or, in some cases, months. Their approach, which was 
successfully tested on a vaccine for rodents, is published in Nature Communications.
Nanoparticles, polymers and sugar
 The study addressed viral-vector vaccines, the most common type of 
vaccine, which normally only last for a few days at room temperature. At
 that point, the viral components of the vaccines lose their structural 
integrity. “These components fluctuate by their very nature,” says 
Stellacci, head of SUNMIL - Constellium Chair. “They are combined in a 
stable form, and the low temperature maintains that balance. But the 
thermally induced fluctuations eventually lead to a loss of integrity of
 the viral vector.” The scientists’ approach, which consists of 
stabilizing the vaccines against such fluctuations through simple 
biocompatible additives, has delivered excellent results.
In their
 first approach, osmotic pressure is applied on the inactivated viruses 
(the main component of the vaccine) using a cloud of negatively charged 
nanoparticles. The virus is already subject to an outward osmotic 
pressure due to its genetic material (RNA or DNA), which has a high 
negative charge and is held inside the virus. The nanoparticles form a 
cloud of negatively charged objects that cannot enter the virus, thus 
generating counter-osmotic pressure that keeps the virus intact. “With 
this method, infectivity for a virus reached a half-life of 20 days,” 
says Stellacci.
The second approach consists in stiffening the 
virus’s capsid, which envelops the inactivated virus, by adding 
polymers. This additive mainly stabilizes the virus by slowing its 
oscillations by changing the stiffness of the capsid. As a result, the 
vaccine remained fully intact for 20 days with an estimated half-life of
 ~70 days.
Finally, adding sucrose, a common sugar, to the vaccine
 makes the environment more viscous and slows down fluctuations. “It’s a
 little like adding honey, where all motion is slowed down,” says 
Stellacci. With this third approach, 85% of the vaccine's properties 
were intact after 70 days.
Tests on the Chikungunya virus
 Using these results, the researchers applied their methods to a vaccine
 that is currently in development. They were able to stabilize a vaccine
 against Chikungunya, a tropical virus, for 10 days, and then 
successfully inoculated mice with it. “The next step will be to run more
 extensive tests on specific vaccines, possibly combining the three 
different approaches.”
Cheaper access
 This 
study could really impact the effort to increase immunization coverage. 
Currently, in areas where electricity and refrigeration are limited, 
vaccines are moved from one refrigerated space to the next and then 
delivered to recipients in coolers. This complicated process accounts 
for nearly 80% of the cost of vaccination programs. And that, up until 
now, has been a significant impediment.
Source: 
M. Pelliccia, P. Andreozzi, J. Paulose, M. D’Alicarnasso, V. Cagno, M. 
Donalisio, A. Civra, R. M. Broeckel, N. Haese, P. Jacob Silva, R P. 
Carney, V. Marjoma, D. N. Streblow, D. Lembo, F. Stellacci, V. Vitelli 
& S. Krol.Additives to improve thermal stability of adenoviruses from hours to months: implications for vaccine storage.Nature Communications
